Shares of drugmaker Eli Lilly (LLY) got a price target bump by Mizuho on the strength of weight-loss drug tirzepatide. I need to lose about 15 pounds, but I am working on it without taking another drug. Let's check out the charts and indicators.
More from Investing
The technical indicators of the provider of human resources and payroll services are not favorable at present.
All of the talk around recession that had abated, at least for a day, returned with a vengeance, supported by a Cathie Wood interview.
There may be some short-term trades and perhaps a few buying opportunities of unfairly hit stocks, but it just isn't the time to be active.
The maker of building products appears significantly undervalued based on its results and earnings prospects; here's how to play it.
Naspers and its investment-holding company Prosus will sell down their Tencent stake and buy their own shares, with both companies trading at big discounts to NAV.